Genomic Health (GHDX) Tops Q3 EPS by 25c, Raises FY Guidance

Genomic Health (NASDAQ: GHDX) reported Q3 EPS of $0.32, $0.25 better than the analyst estimate of $0.07. Revenue for the quarter came in at $101.3 million versus the consensus estimate of $94.36 million.

GUIDANCE:

Genomic Health sees FY2018 EPS of $1.03-$1.08, versus the consensus of $0.53. Genomic Health sees FY2018 revenue of $389-391 million, versus the consensus of $380.9 million.

For earnings history and earnings-related data on Genomic Health (GHDX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c